<DOC>
	<DOCNO>NCT01018160</DOCNO>
	<brief_summary>The purpose study examine treatment profile approximately 1,000 adult patient gastroesophageal reflux begin raberpazole sodium treatment 4 month , assess patient ' adherence study drug .</brief_summary>
	<brief_title>Practice Patient Compliance PPI ( Proton Pump Inhibitors ) Treatment Gastroesophageal Reflux South Korea</brief_title>
	<detailed_description>This study multicenter , open-labeled , prospective , phase IV , observational study patient visit gastroenterology department . The purpose study examine treatment profile approximately 1,000 adult patient gastroesophageal reflux ( GERD ) begin raberpazole sodium treatment 4 month assess patient ' adherence study drug . The primary objective examine treatment profile gastroesophageal reflux secondary tertiary clinical center . The secondary objective examine GERD patient ' adherence study drug ( rabeprazole sodium ) treatment period . Of patient visit study center complain gastroesophageal reflux symptom study period , deem need rabeprazole sodium administration investigator 's discretion consider study . The main outcome measure pattern gastroesophageal reflux management ( eg . treatment duration initial therapy etc ) compliance proton pump inhibitor treatment.The compliance data ( number tablet take ) calculate clinical visit count number dispense tablet remain . Also , investigator observe gastroesophageal reflux symptom free rate end initial therapy , gastrointestinal ( GI ) symptom relief safety information visit . Study period 4 month . During study , standardize treatment stipulate , patient may receive treatment consider physician . Rabeprazole sodium 10 mg - 20 mg tablet daily 4months .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Rabeprazole</mesh_term>
	<mesh_term>Proton Pump Inhibitors</mesh_term>
	<criteria>Patients complain heartburn acid regurgitation , typical GERD symptom , week After full explanation observational study , patient fully understand sign write consent form Patients take rabeprazole sodium within last four week Patients hypersensitive active ingredient rabeprazole sodium benzimidazole Patient digestive tract diseases GERD ( gastrointestinal cancer , liver disease , pancreatic disease , peptic ulcer , inflammatory digestive tract diseases [ case ulcer , however , scar heal ulcer may include ] ) Patients severe accompany disease include renal impairment , cerebrovascular disease , cardiovascular disease severe respiratory disease Patients must constantly take Proton Pump Inhibitors rabeprazole sodium study period Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Rabeprazole sodium</keyword>
	<keyword>Gastroesophageal Reflux</keyword>
	<keyword>GERD</keyword>
	<keyword>Observational</keyword>
</DOC>